CAS 1365060-22-5

Formula: C11H9ClN2O2S2

InChI: InChI=1S/C11H9ClN2O2S2/c12-10-7(5-1-2-5)8-9(18-10)11(14-4-13-8)17-3-6(15)16/h4-5H,1-3H2,(H,15,16)

InChI key: LJYRIWUQISYYHA-UHFFFAOYSA-N

SMILES: C1CC1C2=C(SC3=C2N=CN=C3SCC(=O)O)Cl

2-((6-CHLORO-7-CYCLOPROPYLTHIENO[3,2-D]PYRIMIDIN-4-YL)THIO)ACETIC ACID

CAS: 1365060-22-5

2-((6-CHLORO-7-CYCLOPROPYLTHIENO[3,2-D]PYRIMIDIN-4-YL)THIO)ACETIC ACID

Purity: 95%

Molecular weight: 300.7799988

Ref: 10-F845072

LP-922056

CAS: 1365060-22-5

LP-922056

Formula: C₁₁H₉ClN₂O₂S₂

Purity: 99.5%

Molecular weight: 300.78

Ref: 54-BUP02908

LP-922056

CAS: 1365060-22-5

LP-922056 is an inhibitor of Notum Pectinacetylesterase with EC50 values of 21 nM, 55 nM for human and mouse, respectively.

Formula: C₁₁H₉ClN₂O₂S₂

Purity: 99.84%

Color and Shape: White Solid

Molecular weight: 300.784

Ref: TM-T38776

2-((6-Chloro-7-Cyclopropylthieno[3,2-D]Pyrimidin-4-Yl)Thio)Acetic Acid

CAS: 1365060-22-5

Formula: C₁₁H₉ClN₂O₂S₂

Purity: 98%

Molecular weight: 300.7844

Ref: IN-DA009XT5

LP 922056

CAS: 1365060-22-5

LP 922056 is a drug that inhibits the dopamine transporter and has been shown to be effective in treating Parkinson's disease. It has also been shown to be effective in treating osteoporosis and osteopenia, which are characterized by low bone mineral density and increased risk of fracture. LP 922056 increases bone mineral density by inhibiting the reuptake of dopamine from the synapse, thereby increasing dopamine levels in the brain. This increase in dopamine levels stimulates new bone formation and leads to an increase in bone mineral density.

Formula: C₁₁H₉ClN₂O₂S₂

Purity: Min. 95%

Molecular weight: 300.8 g/mol

Ref: 3D-QEC06022